Johnson & Johnson (JNJ) Lifted to Buy at Vetr

Johnson & Johnson (NYSE:JNJ) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The brokerage currently has a $150.89 target price on the stock. Vetr‘s price objective would suggest a potential upside of 4.21% from the company’s current price.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus increased their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Citigroup increased their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Argus increased their price target on Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a research note on Wednesday, October 18th. Finally, BMO Capital Markets increased their price target on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $145.69.

Shares of Johnson & Johnson (NYSE JNJ) traded up $0.82 during trading hours on Thursday, reaching $144.79. The company’s stock had a trading volume of 4,962,045 shares, compared to its average volume of 5,920,000. The company has a market cap of $388,980.00, a P/E ratio of 25.14, a PEG ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $145.68.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.68 EPS. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. lifted its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after acquiring an additional 130,437 shares in the last quarter. FMR LLC raised its holdings in shares of Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors raised its holdings in shares of Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after acquiring an additional 1,050,000 shares in the last quarter. 65.70% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Lifted to Buy at Vetr” was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/11/johnson-johnson-jnj-lifted-to-buy-at-vetr.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit